YESINTEK is approved for Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis, offering a ...

Biotechnology firm Biocon Ltd on Monday (February 24) said its unit Biocon Biologics announced the US market availability of ...

YESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.

Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced that YESINTEK™ (ustekinumab-kfce) is now ...

Johnson & Johnson (NYSE:JNJ) is reportedly suing Samsung Bioepis for breach of contract related to the launch of a biosimilar ...

NTPC along with its arm NTPC Green Energy signed multiple MoUs with Madhya Pradesh government to invest over Rs 2 lakh crore ...

Biocon Biologics has introduced a biosimilar drug, YESINTEK, in the U.S. for treating autoimmune diseases like Crohn's disease, ulcerative colitis, and psoriasis. The launch represents a commitment to ...

Biocon Biologics (BBL), a fully integrated global biosimilars company and a subsidiary of Biocon (BSE code: 532523, NSE: BIOCON), today announced that YESINTEK (ustekinumab-kfce) is now available to ...

MUMBAI:  Biocon Biologics Ltd has announced the US launch of Yesintek  (ustekinumab-kfce), one of the first biosimilars to Janssen's Stelara® to enter the American market. The biosimilar, approved by ...

Biocon aims to grow through new product launches in generics and biosimilars, bolstered by the Viatris acquisition. This ...

A number of stocks are set to be in focus during the coming session on Dalal Street, including NTPC, NTPC Green, SBI Card and ...

Biocon Biologics launches YESINTEK (ustekinumab-kfce), a biosimilar for Crohn's disease, ulcerative colitis, plaque psoriasis ...